Breast Cancer
Multiple Myeloma
Lung Cancer
Immuno-Oncology News
Gynecologic Oncology
Gastrointestinal Cancer
Colorectal Cancer
Ovarian Cancer
Prostate Cancer
Precision Medicine in Oncology
®
Neoadjuvant HER2+
Bone Metastases
Brain Cancer
Business Management
CAR T-cell Therapy
Chronic Lymphocytic Leukemia
Genitourinary Cancers
Head & Neck Cancers
Hematologic Oncology
Immunotherapy in GU Cancers
Immunotherapy in Lung Cancer
Immunotherapy in Melanoma
Mantle Cell Lymphoma
Melanoma & Skin Cancer
Non-Hodgkin Lymphoma
Oncology Nursing News
Patient Resources
Sarcomas/TGCT
Special Reports in Personalized Cancer Care
Supportive Care
Online CME
Interactive Publications
SELECT A TOPIC
CURRENT VIEW
All Specialties
▲
Education ▲
Education ▼
Register
|
Login
Conference Coverage
Videos
NewsNetwork
OncLive
®
TV
Peer Exchange
Insights
Attend An Event
State of the Science Summit
Regional Seminar Series
PER Conferences
Giants of Cancer Care
ISGIO
Webinars
OncLive Community
SPECIALTY TOPICS
CURRENTLY VIEWING
All Specialties
Breast Cancer
Multiple Myeloma
Lung Cancer
Immuno-Oncology News
Gynecologic Oncology
Gastrointestinal Cancer
Colorectal Cancer
Ovarian Cancer
Prostate Cancer
Precision Medicine in Oncology
®
Neoadjuvant HER2+
More >>
OncLive TV: Neeraj Agarwal, MD
<< Back to Our Featured Experts
Dr. Agarwal on the QoL With Apalutamide in Metastatic Castration-Sensitive Prostate Cancer
Dr. Agarwal on the Safety Profile of Enzalutamide/Talazoparib in mCRPC
Dr. Agarwal on Patient Selection in Frontline Advanced RCC
Dr. Agarwal on Updated Results of the JAVELIN Renal 101 Trial in Advanced RCC
Dr. Agarwal on Unmet Needs in mRCC
Dr. Agarwal on the Combination of Lenvatinib and Everolimus in mRCC
Dr. Agarwal Discusses Results of KEYNOTE-426 in mRCC
Dr. Agarwal on Second-Line Therapy Selection in Metastatic RCC
Dr. Agarwal on Next Steps in Kidney Cancer
Dr. Agarwal on Emerging Immunotherapeutic Combinations in Kidney Cancer
Dr. Agarwal on Frontline Treatment in Kidney Cancer
Dr. Agarwal Discusses Recent FDA Approvals in RCC
Dr. Agarwal on Treatment for Newly Diagnosed Prostate Cancer
Dr. Agarwal on the Advantages of Docetaxel in Prostate Cancer
Dr. Agarwal on the CheckMate-214 Trial for Kidney Cancer
Dr. Agarwal on Androgen Receptor Inhibitors for Prostate Cancer
Dr. Agarwal on Remaining Questions With Renal Cell Carcinoma
Dr. Agarwal on Potential Agents for Metastatic Hormone-Sensitive Prostate Cancer
Dr. Agarwal on the STAMPEDE and LATITUDE Trials for Prostate Cancer
Dr. Agarwal on Toxicities With Checkpoint Inhibitors in RCC
Dr. Neeraj Agarwal on PROSTVAC and Other Immunotherapies in Prostate Cancer
Oncology Specialists
A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z
Orazio Caffo, MD
Joseph A. Califano, MD
Michael A. Caligiuri, MD
Rena D. Callahan, MD
Natalie S. Callander, MD
D. Ross Camidge, MD, PhD
David Ross Camidge, MD, PhD
Steven Campbell, MD, PhD
Susana M. Campos, MD
Susana Campos, MD, MPH
Maria D. Cappellini, MD
David Carbone, MD, PhD
David P. Carbone, MD, PhD
Fatima Cardoso, MD
Lisa Carey, MD
Lisa A. Carey, MD
Jennifer Carlisle, MD
Grant W. Carlson, MD
Giselle Carnaby, PhD
Hetty Carraway
Peter R. Carroll, MD
Kenneth R. Carson, MD
Richard Carvajal, MD
Richard D. Carvajal, MD
Tina Cascone, MD, PhD
Jorge J. Castillo, MD
Erik P. Castle, MD
Daniel Catenacci, MD
Charles Catton, MD
Abigail S. Caudle, MD
Michele Cavo, MD
David Cella, PhD
Andrea De Censi, MD
Andrea Cercek, MD
Robert J. Cerfolio, MD
Robert J. Cerfolio, MD, MBA
Francisco Cervantes, MD, PhD
Abraham Chachoua, MD
Jamie E. Chaft, MD
Anees B. Chagpar, MD
Anees B. Chagpar, MD, FACS
Andrew T. Chan, MD
Arlene Chan, MD
Jennifer Chan, MD, MPH
Emily Chan, MD, PhD
Asher A. Chanan-Khan, MD
Sarat Chandarlapaty, MD, PhD
Jenny C. Chang, MD
David D. Chang, MD, PhD
Joseph Chao, MD
Nelson Jen An Chao, MD
Samuel Chao, MD
Brian F. Chapin, MD
Paul Chapman, MD
Paul B. Chapman, MD
Ajai Chari, MD
Dana Chase, MD
Dana M. Chase, MD, FACOG
Ian Chau, MD
Preet M. Chaudhary, MD, PhD
Julio Chavez, MD
Moon S. Chen, Jr., PhD
Selina Chen-Kiang, PhD
Ann-Lii Cheng, MD
Haiying Cheng, MD
Yee Chung Cheng, MD
Bruce D. Cheson, MD
Saurabh Chhabra, MD, MS
Kim Chi, MD
Susan N. Chi, MD
Anne Chiang, MD, PhD
A. Jo Chien, MD
Gabriela Chiorean, MD
Rowan T. Chlebowski, MD, PhD
Hearn Jay Cho, MD, PhD
Humberto Choi, MD
Seungtaek L. Choi, MD
Sung W. Choi, MD
Michael A. Choti, MD
Atish D. Choudhury, MD, PhD
Toni Choueiri, MD
Toni K. Choueiri, MD
Simon Chowdhury, MA, MBBS, MRCP, PhD
Simon Chowdhury, MD
Simon Chowdhury, PhD, MA, MBBS, MRCP
Hak Choy, MD
Peter L. Choyke, MD
Peter L. Choyke, MD, FACP
Peter Choyke, MD, FACR
Quincy Chu, MD
Vincent Chung, MD
Hyun C. Chung, MD, PhD
Thomas M. Churilla, MD
Jane E. Churpek, MD
David Cibula, MD
Joseph Ciccolini, PhD
Jay Ciezki, MD
Kristen Ciombor, MD, MSCI
Peter Clark, MD
Jordan Clark
Jeffrey M. Clarke, MD
Loren Clarke, MD
Anthony J. Cmelak, MD
Patrick W. Cobb, MD
Melody A. Cobleigh, MD
Adam D. Cohen, MD
Deirdre J. Cohen, MD
Emil Israel Cohen, MD
Ezra Cohen, MD
Jonathon B. Cohen, MD
Joshua G. Cohen, MD
Jonathon B. Cohen, MD, MS
Howard Cohen, RPh, MS, FASHP
Dr. Yael Cohen
Allen L. Cohn, MD
Daniel G. Coit, MD
Robert E. Coleman, MBBS, MD, FRCP, FRCPE
Robert Coleman, MD
Robert L. Coleman, MD
Robert L. Coleman, MD, FACOG, FACS
Eric A. Collisson, MD
Raoul Concepcion, MD
Raoul S. Concepcion, MD
Raoul S. Concepcion, MD, FACS
Thierry Conroy, MD
Michael Cookson, MD
Matthew Cooperberg, MD
Matthew R. Cooperberg, MD, MPH
Larry J. Copeland, MD
Kimberly S. Corbin, MD
Ryan B. Corcoran, MD, PhD
Paul G. Corn, MD, PhD
Jorge E. Cortes, MD
Casey M. Cosgrove, MD
Daniel B. Costa, MD, PhD, MMSc
Anthony Costales, MD
Giovan Giuseppe Di Costanzo, MD
Daniel Costin, MD
Daniel R. Couriel, MD
Steven Coutre, MD
Andrew J. Cowan, MD
Sarah Crafton, MD
Christopher Crane, MD
Erin K. Crane, MD, MPH
E. David Crawford, MD
Jeffrey Crawford, MD
Chiara Cremolini, MD
Mihaela C. Cristea, MD
Massimo Cristofanilli, MD
Brian D. Crompton, MD
Giuseppe Curigliano, MD, PhD
Walter J. Curran, Jr., MD
Eric Van Cutsem, MD, PhD
OncLive News Network On Location: ASH 2019 Day 3
Trending Now
Navitoclax Overcomes Ruxolitinib Resistance for Myelofibrosis
Dr. Atkins on Long-Term Outcomes of the CheckMate-204 Trial in Melanoma
Tucatinib Boosts Survival in HER2+ Breast Cancer, FDA Submission Imminent
KTE-X19 Shows High CR Rates for MCL, FDA Submission Planned
Publications
Covering Every Angle of Oncology Practice. Click a cover below, to view more.
x
Subscribe